交銀國際:上調麗珠醫藥(1513.HK)目標價至43港元 評級“買入”
交銀國際發報告指,上調麗珠醫藥(1513.HK)目標價4.9%,由41港元調高至43港元,相當於2021年市盈率17倍,重申“買入”評級。
該行表示,麗珠醫藥的抗體檢測試劑盒上市後獲得中國及歐盟雙重認證,預計第二季試劑盒銷售超過2000萬人份,可帶動全年利潤增8%至13%。
另外,專科藥艾普拉唑有温和的醫保降價支持,其作為第二代PPI抑制劑的技術優勢,加上目前市佔率較低,將推動其加快進入醫院及之後的增長。
集團2018年來成功進行產品結構轉型,除了重磅藥物艾普拉唑及亮丙瑞林微球維持高雙位數字增長,二線消化道藥物整體業績表現積極,預計2020至2022年消化道藥物分別同比增長22%、36%及30%。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.